Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Qualified Small Business Stock (QSBS)

Investors can unlock significant tax advantages by understanding how this specialized equity structure shields millions in capital gains from taxation

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale · InvestmentQsbsSmall BusinessTax Benefits
Share

Key takeaways

01

Investors can unlock significant tax advantages by understanding how this specialized equity structure shields millions in capital gains from taxation

In this episode of Weaver: The Alternative Edge, hosts Blayne Lowary and Vardeep Mann delve into the intricacies of Qualified Small Business Stock (QSBS). This conversation provides crucial information for investors and fund managers looking to maximize tax benefits through QSBS. Lowary and Mann bring valuable insights into how QSBS can be a significant advantage for non-corporate taxpayers, providing substantial exclusions on capital gains.

Key Points:

  • QSBS can provide substantial tax exclusions, potentially excluding up to $40 million of gain from taxable income.
  • Claiming QSBS benefits requires proper documentation and portfolio company representation.
  • Investors should be aware of pitfalls like warehouse investments and subsequent closes, which may disqualify QSBS eligibility.

Lowary and Mann discuss the key aspects and potential challenges of Qualified Small Business Stock (QSBS). They emphasize the importance of understanding QSBS eligibility criteria, including the need for proper documentation and portfolio company representations. "One of the requirements for stock to be eligible for QSBS is it has to be received upon original issuance," Lowary said.

One of the requirements for stock to be eligible for QSBS is it has to be received upon original issuance.
— Blayne Lowary

Additionally, the discussion covers critical gray areas, such as the impact of convertible notes and SAFEs on QSBS eligibility and the complexities surrounding carried interest. "Convertible notes and SAFEs are a gray area, specifically regarding when the clock starts for the five-year hold period," Mann said.

Convertible notes and SAFEs are a gray area, specifically regarding when the clock starts for the five-year hold period.
— Vardeep Mann

This episode serves as an essential guide for those navigating the QSBS landscape.

Subscribe and listen to future episodes of Weaver: The Alternative Edge, on Apple Podcasts or Spotify.

©2024

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

M
MarketScale

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512